NCI-2021-09617

A Multicenter, Phase IB/II Study of Abemaciclib in Combination with Bicalutamide for Androgen Receptor-positive, HER2-negative Metastatic Breast Cancer

The study is testing a combination of two medicines for a specific type of breast cancer that has a protein called Androgen Receptor, which is usually found in male hormones. The cancer cells in this type of cancer respond to this protein. However, they don't have another protein called HER2. The study is focused on two medicines: Abemaciclib: This is a medicine that can slow down the growth of cancer cells by targeting specific proteins. Bicalutamide: This medicine is used to block the effects of male hormones. The study wants to see if using Abemaciclib together with Bicalutamide can work well in treating this specific type of breast cancer. They're checking if this combination can help shrink the cancer and slow its growth. In Phase IB, they'll start with a smaller dose and see how people react to it. If it's safe and well-tolerated, they'll move on to Phase II, where they'll give this combination to a larger group to get more information about how well it works.

For more information about the trial, click the link below:

https://clinicaltrials.gov/ct2/show/NCT05095207

NCI-2021-09617

Clinical Trial Site: Mount Sinai

To see all available clinical trials click here.